Dosage Forms & Drug Delivery Systems – Page 43

Sedimentation Oos during inspection readiness: manufacturing vs lab root cause decision tree

Identifying symptoms related to sedimentation is the first step in the investigation process. Careful observation and documentation can reveal critical signals that indicate a potential OOS situation. Symptoms can manifest…

Post-Approval Change Failure for modified release platforms: risk assessment and validation impact analysis

Identifying symptoms indicative of a post-approval change failure is critical in the initial stages of the investigation. Here are common signals encountered in the manufacturing or laboratory settings:Click to read…

Method Transfer Failure for innovative delivery systems: how to document for FDA/EMA/MHRA review

Identifying the early warnings of method transfer failure is vital. Common symptoms include:Click to read the full article.

Cpv Trending Gap after formulation change: decision tree for lab vs manufacturing root cause

Identifying the symptoms that indicate a potential Cpv trending gap is the first step in effective investigation. Common signals you may encounter include:Click to read the full article.

Assay Oos during bulk hold: investigation steps with CAPA evidence

Identifying symptoms is the first step in addressing an OOS situation. Symptoms of an assay OOS during bulk hold can emerge from various sources, including the laboratory, production floor, and…

Scale-Up Failure after formulation change: control strategy build-out for inspections

Understanding the symptoms or signals that indicate a scale-up failure is the first step in initiating an investigation. Common signs to look for during production or quality control include:Click to…

Oos Release Profile after formulation change: how to document for FDA/EMA/MHRA review

Documenting OOS Release Profiles Following Formulation Changes: A Guide for Compliance and Investigation In the pharmaceutical manufacturing landscape, deviations such as Out-of-Specification (OOS) results post-formulation change present complex challenges. These…

Preservative Miscalculation during inspection readiness: sanitation, water, and EM checks

Identifying the symptoms of preservative miscalculations early can mitigate the risk of downstream impacts on batch quality and compliance. Common signals that can indicate a preservative miscalculation include:Click to read…

Cpv Trending Gap for nanoformulations: decision tree for lab vs manufacturing root cause

Detecting and documenting symptoms or signals is crucial for initiating an investigation into Cpv trending gaps for nanoformulations. Common indicators include:Click to read the full article.

E&L Failure for long-acting injectables: how to document for FDA/EMA/MHRA review

Symptoms of E&L failures often manifest as deviations in product quality or laboratory test results, primarily during stability testing or routine quality control measures. Some key signals include:Click to read…

Control Strategy Weakness after formulation change: decision tree for lab vs manufacturing root cause

Identifying symptoms or signals is paramount in recognizing a control strategy weakness following a formulation change. Symptoms may manifest as Out of Specification (OOS) results, deviations from established batch records,…

Phase Separation after supplier change: GMP documentation for FDA/EMA/MHRA review

Identifying symptoms of phase separation is critical for an effective response. Common signals on the manufacturing floor or in the laboratory include:Click to read the full article.